Asked by: Chris Bryant (Labour - Rhondda)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, if she will publish the attendance of each meeting of the AI and Copyright Code of Practice Working Group in (a) 2023 and (b) 2024.
Answered by Saqib Bhatti - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The working group on copyright and AI met under terms of reference available at https://www.gov.uk/guidance/the-governments-code-of-practice-on-copyright-and-ai. This information for 2023 has previously been disclosed pursuant to a Freedom of Information request, and is set out in the following table:
Date of meeting | Attendees, by organisation |
05/06/2023 (AI firms and research sector only) | The Entrepreneurs Network; IP Federation; Stability AI; Knowledge Rights 21; Google DeepMind; Tech UK; British Library; UK Research and Innovation (UKRI); Microsoft; Synthesia IPO; Department for Culture, Media and Sport (DCMS); Competition and Markets Authority (CMA) |
06/06/2023 (right holders only) | RELX; Professional Publishers Association; British Association of Picture Library Agencies (BAPLA); News Media Association; Alliance for IP; UK Music; NLA Media Access; Association of Photographers; Financial Times; Copyright Licensing Agency; British Phonographic Industry (BPI); Equity; Publishers Association; Creators’ Rights Alliance; Music Publishers Association; British Screen Forum; Design and Artists Copyright Society (DACS); Copyright Clearance Center; British Copyright Council; British Broadcasting Corporation (BBC); Premier League IPO; DCMS; CMA |
13/06/2023 | RELX; Professional Publishers Association; The Entrepreneurs Network; IP Federation; Stability AI; Knowledge Rights 21; News Media Association; Alliance for IP; Council of Music Makers; UK Music; NLA Media Access; Association of Photographers; Copyright Licensing Agency; Financial Times; BAPLA; Google DeepMind; Tech UK; Equity; vAIsual; British Library; Creators’ Rights Alliance; Music Publishers Association; UKRI; British Screen Forum; DACS; Copyright Clearance Center; British Copyright Council; Microsoft; BPI; Innovate UK; BBC IPO; DCMS; Office for AI (OAI); CMA |
30/06/2023 | Professional Publishers Association; BAPLA; Knowledge Rights 21; Publishers Association; News Media Association; Alliance for IP; The Entrepreneurs Network; UK Music; NLA Media Access; Association of Photographers; Copyright Licensing Agency; Financial Times; Startup Coalition; Equity; vAIsual; British Library; Creators’ Rights Alliance; Music Publishers Association; UKRI; British Screen Forum; DACS; Copyright Clearance Center; British Copyright Council; Microsoft; BPI; Tech UK; Innovate UK; BBC; RELX; Council of Music Makers IPO; DCMS; OAI |
13/09/2023 (right holders only) | Professional Publishers Association; British Film Institute (BFI); Association of Photographers; Copyright Licensing Agency; Condé Nast; Guardian Media Group; Publishers Association; BPI; Equity IPO |
22/09/2023 | Association of Photographers; Getty Images; BBC; vAIsual; Microsoft; Music Publishers Association; Startup Coalition; British Copyright Council; Stability AI IPO |
26/09/2023 | RELX; Copyright Clearance Center; Copyright Licensing Agency; Alliance for IP; vAIsual; The Entrepreneurs Network; British Copyright Council; IP Federation; Synthesia; Publishers Association; WB Discovery; Council of Music Makers; Financial Times; Guardian Media Group; Startup Coalition |
29/09/2023 | Alliance for IP; British Copyright Council; Creators’ Rights Alliance; Equity; Stability AI; DACS; Microsoft; Innovate UK; BFI; British Screen Forum; Reading University; UK Music; Professional Publishers Association IPO |
04/10/2023 | Creators’ Rights Alliance; Equity; UK Music; Professional Publishers Association; Tech UK; News Media Association; Association of Photographers; Getty Images; The Entrepreneurs Network; BPI IPO |
05/10/2023 (AI firms only) | The Entrepreneurs Network; Startup Coalition; Microsoft; Stability AI; vAIsual IPO |
06/10/2023 | British Library; UKRI; BFI; Tech UK; Alliance for IP; Professional Publishers Association; RELX; Copyright Clearance Center; Turing Institute; Knowledge Rights 21 IPO |
12/10/2023 | Professional Publishers Association; BAPLA; The Entrepreneurs Network; Knowledge Rights 21; Publishers Association; News Media Association; Alliance for IP; Council of Music Makers; UK Music; NLA Media Access; Association of Photographers; Copyright Licensing Agency; Financial Times; BPI; Startup Coalition; Equity; vAIsual; Guardian Media Group; Creators’ Rights Alliance; Music Publishers Association; UKRI; British Screen Forum; BFI; Copyright Clearance Center; British Copyright Council; IP Federation; Microsoft; Innovate UK; BBC IPO; DCMS; OAI; Department for Science, Innovation and Technology; CMA |
The group did not meet in 2024.
Asked by: Jerome Mayhew (Conservative - Broadland)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what recent discussions she has had with Cabinet colleagues on encouraging Qatari investment in UK research and development.
Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)
Through all our global partnerships, including those in the Gulf, government is delivering on the UK’s Science and Technology Framework and strengthening UK R&D.
Qatar is an important friend to the UK and our bilateral relationship includes cooperation across many areas. The UK-Qatar Strategic Investment Partnership, signed in May 2022, signalled Qatar’s intention to deploy a further £10bn investment in key UK sectors, such as life science, zero-emissions vehicles and fintech over the next 5 years.
The UK’s new research MoU with Saudi Arabia, which I signed last month, is another example of where we are driving forward partnerships in the region to support UK R&D.
Asked by: Lord Naseby (Conservative - Life peer)
Question to the Department for Business and Trade:
To ask His Majesty's Government why a grant of £8 million was recently paid to Vertical Aerospace to develop a flying taxi company at a time when the firm faced material uncertainty.
Answered by Lord Offord of Garvel - Parliamentary Under Secretary of State (Department for Business and Trade)
A research consortium led by Vertical Aerospace, including four universities, was awarded an Aerospace Technology Institute (ATI) Programme grant to develop propeller technology.
The ATI Programme co-funds UK research and development activity with industry to develop zero-carbon and ultra-efficient aircraft technology. Grants are awarded after a competitive process, with only the best projects recommended - those that offer real innovation, emissions reduction and tangible economic benefits to the UK.
Due diligence checks are completed ahead of all awards, with grants paid in arrears based on activity delivered against an agreed plan. Safeguards are in place in the event of business failure.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how much research funding the National Institute for Health and Care Research and the Medical Research Council have invested in biomedical studies of the causes and treatment of myalgic encephalomyelitis (ME) and non-biomedical studies of ME since 2019.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). Since 2019, the NIHR has awarded £1.9 million for research into myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome. The Medical Research Council (MRC), part of UK Research and Innovation (UKRI), has invested £3.6 million since 2019.
This funding includes the NIHR and UKRI co-funded DecodeME study, a £3.2 million study into the genetic underpinning of ME. The study will analyse samples from 25,000 people with ME, to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. This study aims to increase our understanding of the disease, and therefore contribute to the research base on diagnostic tests and targeted treatments for ME.
In 2020, the NIHR, the Chief Scientist Office in Scotland, and the MRC also funded the James Lind Alliance Priority Setting Partnership for ME, facilitated by the charity Action for ME. The report sets out the top 10 research priorities for ME. These recommendations have been co-produced through a process led by a steering group of people living with ME, carers, and clinicians.
In the interim delivery plan on ME, the Department recognised that there has been a relatively low amount of biomedical research funded on ME, compared with disease burden. The NIHR and MRC welcome applications for further biomedical research into ME. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all disease areas, the amount of funding depends on the volume and quality of scientific activity.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what progress they have made on the funding of biomedical research into myalgic encephalomyelitis (ME) since the then Parliamentary Under Secretary of State for Health and Social Care stated on 24 January 2019 that “there have not been good enough research proposals in the ME space, partly because of the stigma … and partly because of the division in the medical community”.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). Since 2019, the NIHR has awarded £1.9 million for research into myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome. The Medical Research Council (MRC), part of UK Research and Innovation (UKRI), has invested £3.6 million since 2019.
This funding includes the NIHR and UKRI co-funded DecodeME study, a £3.2 million study into the genetic underpinning of ME. The study will analyse samples from 25,000 people with ME, to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. This study aims to increase our understanding of the disease, and therefore contribute to the research base on diagnostic tests and targeted treatments for ME.
In 2020, the NIHR, the Chief Scientist Office in Scotland, and the MRC also funded the James Lind Alliance Priority Setting Partnership for ME, facilitated by the charity Action for ME. The report sets out the top 10 research priorities for ME. These recommendations have been co-produced through a process led by a steering group of people living with ME, carers, and clinicians.
In the interim delivery plan on ME, the Department recognised that there has been a relatively low amount of biomedical research funded on ME, compared with disease burden. The NIHR and MRC welcome applications for further biomedical research into ME. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all disease areas, the amount of funding depends on the volume and quality of scientific activity.
Asked by: Lord Jackson of Peterborough (Conservative - Life peer)
Question to the Department for Energy Security & Net Zero:
To ask His Majesty's Government what support, if any, they will provide to Anglia Ruskin University in their ambition to establish a Global Innovation Centre for Energy Transition in Peterborough.
Answered by Lord Callanan - Parliamentary Under Secretary of State (Department for Energy Security and Net Zero)
The Government runs a significant range of research and innovation programmes to support the transition of the energy system. This includes through UK Research and Innovation, the UK’s agency investing in science and research and interested parties such as Anglia Ruskin University are welcome to apply for these as opportunities arise. More information can be found on UKRI’s online Funding Finder Tool, where all funding opportunities are published (https://www.ukri.org/opportunity/).
In addition, recent investments are set out in the Government’s UK Net Zero Research and Innovation Delivery Plan 2022-2025.
Asked by: Robert Buckland (Conservative - South Swindon)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how she plans to promote research into new models of (a) assessment and (b) support.
Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)
The government’s November 2023 ‘Response to the Independent Review of the RDI Organisational Landscape’ announced the creation of a new Metascience Unit, jointly run across the Department for Science, Innovation and Technology and UK Research and Innovation (UKRI), with an initial funding commitment of £10m. The unit will deliver a competitive grants programme and will also conduct experiments to test and robustly evaluate the effectiveness of changes in the funding processes delivered by UKRI.
This programme of work is intended to generate evidence on more effective ways of funding and supporting scientific research.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to ensure that the National Institute for Health and Care Research, the Medical Research Council, and the UK Research and Innovation work together collaboratively to ensure progress on funding brain tumour research.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23, and the NIHR spends more on cancer than any other disease group.
In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission, through the NIHR. Since this announcement, the NIHR has committed £11.3 million across 17 projects, with the Medical Research Council (MRC) awarding £10.4 million. There is still funding available from the original £40 million, and we expect to spend more as new research progresses.
The Department is taking steps to ensure that funders work closely together to coordinate work along the translational pathway, from the discovery and early translational science typically supported by the MRC, feeding through to the applied health and care research funded by the NIHR. These steps include convening a brain cancer research roundtable in May 2024, to bring together research experts and funders, to determine how to accelerate research efforts in this area.
As an example of coordination, the Efficacy and Mechanism Evaluation (EME) Programme is a partnership between the MRC and the NIHR, supporting research in the mechanisms of diseases, and treatments which have the potential to make a step-change in the promotion of health, treatment of disease, and improvement of rehabilitation or long-term care. The EME’s portfolio includes a £1.5 million clinical trial testing the effectiveness of a targeted form of proton beam radiotherapy for a type of brain cancer called oligodendroglioma. The NIHR also coordinates with the MRC to complement their investments, such as a £2 million investment supporting researchers to understand and treat cancers with exceptionally poor survival rates, including cancer of the brain, lung, and oesophagus.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to reduce the adverse disparity in survival rates for brain tumour patients compared to other cancers whose treatment attracts greater levels of funding.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). The NIHR’s research expenditure for all cancers was £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group.
In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission through the NIHR. Brain tumours are a difficult research area with a relatively small research community, so we are taking actions to grow the field, such as workshops for researchers, and research training for clinicians. In addition to research programme spend on projects, NIHR research infrastructure supports brain tumour research studies, mainly in the National Health Service. Between 2018 and 2022, UK Research and Innovation, including the Medical Research Council, awarded £23.2 million in brain tumour research funding.
The Government is committed to improving the survival rates for all cancers. The latest publicly available figures showed improved survival rates across almost all types of cancer, including brain cancer, since 2010. Early diagnosis is key to improving survival rates, and the Department is working towards the NHS Long Term Plan ambition of diagnosing 75% of stageable cancers at stage 1 and 2 by 2028.
The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. Over 340,000 people received their first cancer treatment in the 12 months to January 2024.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will review spending on (1) gliomas, and (2) astrocytoma cancer, to account for any increase in incidences.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). The NIHR’s research expenditure for all cancers was £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group.
In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission through the NIHR. Brain tumours are a difficult research area with a relatively small research community, so we are taking actions to grow the field, such as workshops for researchers, and research training for clinicians. In addition to research programme spend on projects, NIHR research infrastructure supports brain tumour research studies, mainly in the National Health Service. Between 2018 and 2022, UK Research and Innovation, including the Medical Research Council, awarded £23.2 million in brain tumour research funding.
The Government is committed to improving the survival rates for all cancers. The latest publicly available figures showed improved survival rates across almost all types of cancer, including brain cancer, since 2010. Early diagnosis is key to improving survival rates, and the Department is working towards the NHS Long Term Plan ambition of diagnosing 75% of stageable cancers at stage 1 and 2 by 2028.
The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. Over 340,000 people received their first cancer treatment in the 12 months to January 2024.